Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23692789 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ATSHRHPGD | |
| SCHEMBL17032291 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ATSHRHPGD | |
| SCHEMBL19078503 | 0.90 | MEN1 (0.47) | ALDH1A1MEN1KMT2ATSHRHPGD | |
| SCHEMBL631246 | 0.90 | MEN1 (0.47) | ALDH1A1MEN1KMT2ATSHRHPGD | |
| SCHEMBL6218492 | 0.89 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ATSHRHPGD | |
| SCHEMBL15720999 | 0.89 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ATSHRHPGD | |
| SCHEMBL17756103 | 0.89 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2ATSHRHPGD | |
| SCHEMBL18092280 | 0.89 | GAA (0.49) | ALDH1A1KMT2ATSHRMAPTGAA | |
| SCHEMBL12723118 | 0.88 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ATSHRHPGD | |
| SCHEMBL6907597 | 0.88 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ATSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| EP-4419527-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067355-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| CN-114478528-A | Aroyl-substituted tricyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3567030-B1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC (CN) | 2022-02-09 | — | — | EP | disclosed |
| EP-3883647-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-11040984-B2 | Quinazoline compound for EGFR inhibition | MEDSHINE DISCOVERY INC. (CN) | 2021-06-22 | — | — | US | disclosed |
| US-20200190107-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| WO-2018121758-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | 南京明德新药研发股份有限公司 | 2018-07-05 | — | — | WO | disclosed |
| US-6509003-B2 | N-alkylpiperidine derivatives labeled with radioactive iodine; use in single photon emission computed tomography (SPECT) | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 2003-01-21 | — | — | US | disclosed |
| EP-0989120-B1 | REAGENTS FOR ASSAYING CENTRAL LOCAL ACETYLCHOLINESTERASE ACTIVITY | DAIICHI PURE CHEMICALS CO LTD (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-20020127180-A1 | Reagents for the determination of cerebral regional acetylcholinesterase activity | DAIICHI PURE CHEMICALS CO., LTD (JP) | 2002-09-12 | — | — | US | disclosed |
| US-6306882-B1 | FLUOROALKYLPIPERIDINE ESTERS COGNITION ACTIVATORS AND ALZHEIMER'S | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 2001-10-23 | — | — | US | disclosed |
| EP-0989120-A1 | REAGENTS FOR ASSAYING CENTRAL LOCAL ACETYLCHOLINESTERASE ACTIVITY | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 2000-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040984-B2 | Quinazoline compound for EGFR inhibition | EGFR, ERBB2, ERBB4 | ALDH1A1 3390/4885MEN1 3587/4885KMT2A 3990/4885 |
| US-20200190107-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | EGFR, ERBB2, ERBB4 | ALDH1A1 3390/4885MEN1 3587/4885KMT2A 3990/4885 |
| US-20020127180-A1 | Reagents for the determination of cerebral regional acetylcholinesterase activity | ACHE, BCHE, CHAT | ALDH1A1 61/4885MEN1 1944/4885KMT2A 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.